Clinical research
While the space is just beginning to emerge, therapies for long-haul COVID-19 patients are still very much an unmet need.
Bristol Myers Squibb and Exelixis announced new analysis from the Phase III CheckMate -9ER clinical trial.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for February 9, 2021.
Shares of Avrobio were up nearly 20% in premarket trading after the company posted positive clinical data from its gene therapy trials in three different rare lysomal diseases, Fabry, Gaucher type 1 and cystinosis.
The Swiss health authority Swissmedic rejected AstraZeneca’s rolling authorization application for its COVID-19 vaccine a few days ago, saying more data is needed “to obtain more information about safety, efficacy, and quality.”
Foster City-based Gilead Sciences says its inhaled version of remdesivir, which has been increasingly used in research and practice to combat COVID-19 in hospitalized patients, won’t be available any time soon as it needs more testing in clinical research.
Over the course of 2020, Sanofi saw significant growth in its specialty care sales primarily driven by its blue-chip asset, Dupixent, as well as an increase in vaccine sales that were driven by demand for differentiated influenza vaccines, the company announced in its year-end financial report.
It was a busy week for clinical trial updates. Here’s a look.
AstraZeneca reported that its Phase III KESTREL trial of Imfinzi (durvalumab) failed to meet the primary endpoint of improving overall survival (OS) compared to the EXTREME treatment regimen, which was chemotherapy plus cetuximab, a standard of care.
Less than one week after posting a positive first-look at Phase III vaccine data, Maryland-based Novavax began the rolling review process for authorization of NVX-CoV2373 in the United Kingdom, Canada and the United States.
PRESS RELEASES